Healthcare Industry News: sinusitis
News Release - November 21, 2013
Thomas J. Fogarty, M.D. Joins SinuSys(TM) Corp. Board of DirectorsCompany Intends to Simplify and Improve In-Office Treatment of sinusitis
PALO ALTO, Calif.--(Healthcare Sales & Marketing Network)--SinuSys Corporation, an innovative sinus health company, today announced the appointment of Thomas J. Fogarty, M.D. to its Board of Directors. Dr. Fogarty is joining the board pursuant to a Series D investment by Emergent Medical Partners II, where he serves as Managing Director. The investment in SinuSys Corp. is the first for the new fund.
Dr. Thomas J. Fogarty is an internationally recognized cardiovascular surgeon, inventor, entrepreneur and investor. He has served as founder/co-founder and chairman/board member of more than 30 medical device companies, many of which are based on devices designed and developed by his company, Fogarty Engineering, Inc. He is currently Adjunct Professor of Surgery for Stanford University.
Dr. Fogarty is the author or co-author of more than 125 patents or patent applications, including the industry standard Fogarty Balloon Embolectomy Catheter and the widely-used Aneuryx Stent Graft. As a result of his prolific innovation, he was inducted into the Inventor’s Hall of Fame in 2001.
“We are thrilled to welcome a board member of Dr. Fogarty’s caliber to the company,” said Thomas Schreck, CEO and President of SinuSys Corp. “His broad experience in developing and commercializing meaningful medical devices will be invaluable as we move toward FDA clearance and commercialization, and explore new applications for our proprietary osmotic technology.”
“SinuSys has a truly innovative device that is designed to simplify sinusitis treatment for the physician and improve the patient experience,” said Dr. Fogarty. “I am attracted to opportunities that improve procedures for both physicians and patients, and look forward to helping the company commercialize and expand its unique technology.”
The company’s first device, the Vent-Os™ Sinus Dilation System is designed to resolve sinusitis symptoms in a simple, two-step interventional procedure. The Vent-Os System enables low-pressure, gradual dilation of the maxillary sinus ostia, which is intended to maximize patient tolerability of the procedure in an office setting under local anesthesia. MRK-0139 revA
About SinuSys Corp.
SinuSys Corp. (www.sinusys.com) develops medical device therapies to improve the health of millions of patients suffering from chronic sinusitis worldwide. The company’s proprietary self-expanding, osmotic technology is designed to be atraumatic, tissue-sparing and easy to use, potentially enabling clinicians to intervene at earlier stages of sinus disease. The company seeks to provide improved options for the 20 percent of sinusitis patients whose disease is not resolved with drug therapy.
About Emergent Medical Partners
Emergent Medical Partners is a life sciences investment firm focused on medical device companies in all areas of medicine, including cardiovascular and general surgery, orthopedic surgery, cardiology, radiology, oncology, obesity, gynecology and sleep disorders.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.